(NASDAQ: AYTU) Aytu Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 322.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.35%.
Aytu Biopharma's earnings in 2025 is -$13,562,000.On average, 5 Wall Street analysts forecast AYTU's earnings for 2026 to be -$16,985,054, with the lowest AYTU earnings forecast at -$18,358,845, and the highest AYTU earnings forecast at -$15,299,038. On average, 4 Wall Street analysts forecast AYTU's earnings for 2027 to be -$4,246,264, with the lowest AYTU earnings forecast at -$4,079,743, and the highest AYTU earnings forecast at -$4,371,154.
In 2028, AYTU is forecast to generate $14,255,313 in earnings, with the lowest earnings forecast at $13,696,281 and the highest earnings forecast at $14,674,587.